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AktCalciﬁc aortic valve disease (CAVD) is a leading cardiovascular disorder in the elderly.While aortic valve intersti-
tial cells (AVICs) are the main cells that express osteogenic mediators, the molecular mechanism that mediates
AVIC osteogenic responses is incompletely understood. This study aims to identify pro-osteogenic factors in
human AVICs affected by CAVD.
Methods and results:Microarray analysis identiﬁed 11 up-regulated genes in AVICs of diseased valves. Among
these genes, mRNA levels of neurotrophin 3 (NT3) increased by 2 fold. Higher levels of NT3 protein in diseased
aortic valves and diseased AVICs were conﬁrmed by immunoﬂuorescent staining and immunoblotting, respec-
tively. An exposure of AVICs of normal valves to recombinant human NT3 (0.025–0.10 μg/mL) up-regulated
the production of Runx2, TGF-β1 and BMP-2 in a dose-dependent fashion. NT3 also promotes calcium deposit
formation. The pro-osteogenic effect of NT3 was not affected by neutralization of Toll-like receptor 2 or 4.
Interestingly, mRNA encoding neural growth factor receptors (TrkA, TrkB, TrkC and p75 NTR) was detectable
in human AVICs. Inhibition of Trk receptors markedly reduced the effects of NT3 on Runx2, TGF-β1 and BMP-2
production, calcium deposit formation and Akt phosphorylation. Further, inhibition of Akt also reduced the
pro-osteogenic effects of NT3.
Conclusions:AVICs of diseased human aortic valves express higher levels of NT3. NT3up-regulates the production
of Runx2, TGF-β1 and BMP-2, and promotes calciumdeposit formation in humanAVICs via the Trk–Akt pathway.
Thus, NT3 is a novel pro-osteogenic factor in aortic valves and may play a role in valvular calciﬁcation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Calciﬁc aortic valve disease (CAVD) is a leading cardiovascular disor-
der in people of age 65 or older. CAVD is a progressive condition,
exhibiting a spectrumof pathologic changes, including valvular sclerosis
and calciﬁcation. Secondary left ventricular hypertrophy drives the
development of heart failure. Currently, valve replacement is the only
available therapy. However, several complications, including stroke
and myocardial infarction are associated with aortic valve surgery, and
replaced valves can fail [1]. While randomized clinical trials have beenf Guangdong General Hospital,
Road, Weilun Bldg, Guangzhou
ery, Box C-320, 12700 E 19th
ong.meng@ucdenver.eduperformed to pharmacologically halt the progression of CAVD, none of
them is successful [2–4]. The main reason is that pharmacological
treatments tested are not effective in the late stage of this disease [5,
6]. Research that improves the understanding of the mechanism
responsible for the development and progression of CAVD, or identiﬁes
targets for early pharmacological interventions is of signiﬁcance.
In aortic valve leaﬂetswith early pathological signs of CAVD, valvular
tissue exhibits evidence of inﬂammation and the presence of osteogenic
mediators [7–9], such as bone morphogenetic protein-2 (BMP-2),
transforming growth factor-β1 (TGF-β1), and runt-related transcription
factor 2 (Runx2, a transcription factor for osteoblast differentiation).
Aortic valve interstitial cells (AVICs) are the principal cell type in aortic
valve leaﬂets [10]. Human AVICs are ﬁbroblasts andmyoﬁbroblasts, but
can function as osteoblast-like cells in response to certain stimulation
[11,12]. In this regard, AVICs are found to express Runx2, TGF-β1 and
BMP-2 when exposed to pro-inﬂammatory stimuli in vitro [12–15]. It
appears that the osteogenic responses of AVICs are inciting events in
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lying AVIC osteogenic responses remains incompletely understood.
Nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), neurotrophin-3 (NT3) and neurotrophin-4/5 (NT4/5) are
members of the neurotrophin family. Different neurotrophins display
distinct binding speciﬁcities for particular receptors—NGFbinds prefer-
entially to tropomyosin receptor kinase (Trk)A and BDNF andNT4 binds
to TrkB, while NT3 preferentially binds to TrkC. Interestingly, NT3 can
also bind to TrkA and TrkBwith high afﬁnity [16]. The lowafﬁnity recep-
tor, p75 neurotrophin receptor (p75 NTR), can interact with all
neurotrophins. The main functions of NT3 are to maintain the survival
of existing neurons and to promote the growth and differentiation of
new neurons and synapses [17]. NT3 transcripts have been detected in
the cerebellum, hippocampus, as well as in other tissues, including
placenta, heart, skin, and skeletal muscle [16]. A study by Mizuno and
colleagues found that NT3 up-regulates the mRNA levels of BMP-2 and
alkaline phosphatase (ALP, a biomarker of early osteoblastic differentia-
tion) in cultured human dental pulp cells, indicating a potential pro-
osteogenic effect of this neurotrophin [18]. However, it is unknown
whether NT3 is expressed in human aortic valves, and whether NT3
has a pro-osteogenic effect on human AVICs.
TLR2 and TLR4 are important innate immune receptors that
recognize pathogen-associated molecular patterns (PAMPs) [19] and
danger-associated molecular patterns (DAMPs) [20]. Previous studies
found that AVICs from diseased aortic valves have higher level of TLR2
and TLR4 than AVICs from normal valves [14]. Stimulation of either
TLR2 or TLR4 in human AVICs in vitro up-regulates the expression
of osteogenic mediators [11,14]. Several endogenous agents, such as
oxidized low density lipoprotein (oxLDL) and soluble biglycan, function
as DAMPs to induce the expression of osteogenic mediators [11,14]. To
date, no study indicates whether NT3 functions as a DAMP or not.
We hypothesized that NT3 is expressed in human aortic valves, and
up-regulated NT3 expression in diseased human aortic valves may in-
duce osteogenic responses in human AVICs. The purpose of this study
was to determine: 1) whether NT3 is present in human aortic valves,
2) whether the expression of NT3 is up-regulated in AVICs of diseased
human aortic valves, 3) the effect of NT3 on the osteogenic responses
in human AVICs, and 4) the mechanism by which NT3 exerts its effect
on human AVICs.
2. Materials and methods
2.1. Materials
Neutralizing antibodies against TLR2 and TLR4were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against NT3
and TGF-β1 were purchased from Abcam (Cambridge, MA). Antibody
against BMP-2 was purchased from ProSci, Inc. (Poway, CA). Recombi-
nant human NT3 was obtained from US Biological (Salem, MA).
Antibody against Runx2, phosphorylated extracellular signal-regulated
kinase (ERK)1/2, total ERK1/2, phosphorylated Akt, total Akt and
GAPDH were purchased from Cell Signaling, Inc. (Beverly, MA). K252a,
a speciﬁc pan Trk inhibitor was obtained from Calbiochem (Germany).
Trk isoform-selective Fc chimeras were purchased from R&D Systems,
Inc. (Minneapolis, MN). MK2206, a speciﬁc Akt inhibitor was pur-
chased from Selleckchem (Houston, TX). Medium 199was purchased
from Lonza (Walkersville, MD). Alizarin red S and all other chemicals
and reagents were purchased from Sigma-Aldrich Chemical (St Louis,
MO).
2.2. Cell isolation and culture
Diseased aortic valve leaﬂets were obtained from 7 patients with
CAVD (6males and 1 female; age 61.86± 4.46 years) undergoing aortic
valve replacement at the University of Colorado Hospital. Normal aortic
valve leaﬂets were collected from explanted hearts of 7 patients(6 males and 1 female; age 55.86 ± 1.79 years) with cardiomyopathy
and undergoing heart transplantation at the University of Colorado
Hospital. The valve leaﬂets from explanted hearts were thin and have
no histological abnormality. All patients gave informed consent for the
use of their aortic valves for this study approved by the University of
Colorado Denver Institutional Review Board.
AVICs were isolated and cultured using a previously described
method [12] with modiﬁcation. Brieﬂy, valve leaﬂets were subjected
to an initial digestion with a high concentration of collagenase
(2.5 mg/mL) to remove endothelial cells. Then the remaining tissue
was treated with a low concentration of collagenase (0.8 mg/mL) to
free the interstitial cells. Cells were collected by centrifugation and cul-
tured in M199 growth medium containing penicillin G, streptomycin,
amphotericin B, and 10% fetal bovine serum. AVIC isolates obtained by
using this modiﬁed protocol are lack of endothelial cells as veriﬁed by
von Willebrand factor staining [12]. Each isolate from a separate aortic
valve is used as a cell line. Thus, 7 normal AVIC cell lines and 7 diseased
AVIC cell lines were used in this study. Cells of passages 3 to 6 were
used for this study and were treated when they reached 80% to 90%
conﬂuence.
Levels of NT3mRNA and protein, and mRNA levels of NT3 receptors
TrkA, TrkB, TrkC and p75 NTR in normal and diseased cells were ana-
lyzed by gene microarray, real-time PCR and immunoblotting.
To determine the effect ofNT3 on the osteogenic responses, cells from
normal valves were treated with recombinant human NT3 (0.025–
0.10 μg/mL) for 3 days. Protein levels of Runx2, TGF-β1 and BMP-2 in
cell lysateswere assessed by immunoblotting. Calciumdeposit formation
was analyzed by Alizarin red S staining after AVICs were incubated with
NT3 (0.10 μg/mL) for 14 days in a conditioning medium (growth medi-
um supplemented with 10 mmol/L of β-glycerophosphate, 10 nmol/L
of vitamin D3, 10 nmol/L of dexamethasone, and 8 mmol/L of CaCl2).
The effect of NT3 on phosphorylation of ERK1/2 and Akt was deter-
mined after stimulation of cells with NT3 for 0.5 to 24 h.
To determine the role of TLR2/4, Trk receptors and Akt in NT3-
induced osteogenic responses in human AVICs, neutralizing antibodies
against TLR2 (10 μg/mL) and TLR4 (10 μg/mL), Trk inhibitor K252a
(0.20 μmol/L), Trk isoform-selective Fc chimeras (Fc chimera against
isoforms A, B or C; 2 μg/mL), and Akt inhibitor (MK2206, 5.0 μM) were
added to the cell culture medium 60 min before stimulating with NT3.
Levels of Runx2, TGF-β1 and BMP-2 in cell lysates were assessed by im-
munoblotting. Alizarin red S stainingwas applied to determinewhether
inhibition of Trk receptors or Akt suppresses NT3-induced calcium
deposition.
To determine whether Trk or Akt plays a role in mediating the pro-
osteogenic activity of diseased AVICs in the absence of NT3 stimulation,
Trk inhibitor K252a (0.20 μmol/L) or Akt inhibitor (MK2206; 5.0 μM)
was added to the cell culture medium. Levels of Runx2, TGF-β1 and
BMP-2 in cell lysates were assessed by immunoblotting after treatment
for 3 days in growth medium. Alizarin red S staining was applied to
evaluate the effect of inhibition of Trk receptors or Akt on calcium
deposit formation after treatment for 14 days in the conditioning
medium.2.3. Gene microarray analysis
Gene expression proﬁles of human AVICs were analyzed using
Affymetrix human Gene 1.0 array (Affymetrix, Santa Clara, CA). Ampli-
ﬁed andbiotinylated sense-strand cDNA from total RNAwere generated
using the Ambion®WT Expression Kit (Applied Biosystems, Foster City,
CA). Fragmentation and labeling were performed using the Affymetrix
GeneChip WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA). The
cDNA was applied to Affymetrix human GeneChip® (Affymetrix, Santa
Clara, CA) according to Affymetrix protocol. Data were analyzed using
Partek Genomics Suite 6.6 (Partek Inc.). A cut-off for fold-change was
set at 1.8, with a P-value of ≤0.05.
Table 1
Altered mRNAs in human AVICs of calciﬁc aortic valves.
Gene
symbol
RefSeq Fold-change
(diseased vs. normal)
P-value
(diseased vs. normal)
1 KRTAP1-5 NM_031957 2.13256 0.00629892
2 RAB3B NM_002867 2.25975 0.0199187
3 PSG4 NM_002780 4.25489 0.0263005
4 NT3 NM_002527 1.97169 0.0184045
5 FGD4 NM_139241 1.91591 0.0241249
6 CTPS NM_001905 1.86876 0.00672477
7 MYBL1 NM_001080416 1.90489 0.0161747
8 UBASH3B NM_032873 1.86029 0.0188607
9 PAK3 NM_002578 1.81471 0.0437007
10 STAC NM_003149 1.81985 0.0397348
11 ANKRD1 NM_014391 2.10761 0.0477766
12 SPINLW1 NM_020398 0.491817 0.00360193
13 DRD1 NM_000794 0.417115 0.00659696
14 EVI2A NM_001003927 0.355013 0.0113459
15 KCNE4 NM_080671 0.463565 0.0147415
16 FSHR NM_000145 0.40439 0.0172823
17 ADAMTS5 NM_007038 0.461958 0.0178071
18 EPB41L3 NM_012307 0.48997 0.0194488
19 SLC47A2 NM_152908 0.317509 0.0221616
20 C10orf10 NM_007021 0.470293 0.0222758
21 TSPAN7 NM_004615 0.44412 0.0265327
22 SPON1 NM_006108 0.451007 0.0274257
23 KHDRBS3 NM_006558 0.496052 0.0316491
24 EVI2B NM_006495 0.359865 0.0337025
25 PREX2 NM_024870 0.432608 0.0455236
26 MME NM_007288 0.440545 0.0497784
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Total RNAwas extracted using aQiagenRNeasyMini Kit (Valencia, CA,
USA). Reverse transcription and PCR were performed in triplicate using
iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, CA) and iQ™ SYBR®
Green Supermix according to the manufacturer's instructions. Ampliﬁca-
tion was carried out for 40 cycles including denaturation at 95 °C for 10 s
and annealing/extension at 60 °C for 30 s. The primers used to amplify
speciﬁc cDNA fragments include: TrkA (forward 5′-AACCTCACCATCGT
GAAGAGT, reverse 5′-TGAAGGAG AGATTCAGGCGAC-3′); TrkB (forward
5′-TCGTGGCATTTCCGAGATTGG-3′, reverse 5′-TCGTCATTTGTTTCGGGT
AAA-3′); TrkC (forward 5′-CTTTGCCCAGCCAAGTGTAGT-3′, reverse 5′-
CGTGATGTTGATACTGGCGTT-3′); p75 NTR (forward 5′-CCTACGGCTACT
ACC AGGATG-3′, reverse 5′-CACACGGTGTTCTGCTTGT-3′) and GAPDH
(forward 5′-CATGGC CTCCAAGGAGTAAG-3′, reverse 5′-AGGGGTCTACAT
GGCAAC TG-3′). TrkA, TrkB, TrkC and p75 NTRmRNA levels were quanti-
ﬁed by real-time PCR using the iQ™ 5Multicolor Real-time PCRDetection
system (Bio-Rad, Hercules, CA, USA), normalized against GAPDH mRNA
and calculated using the 2-ΔΔT method [21].
2.5. Immunoﬂuorescence staining
Immunoﬂuorescence staining was applied to detect and localize NT3
in normal and diseased human aortic valves as described previously
[20]. Valvular tissue was dissected and separated from all non-valvular
tissue, and a piece of valve leaﬂet was embedded in the optimal cutting
temperature (OCT) compound. Cryosections of 5 μmthickwere prepared.
After permeabilization with a methanol/acetone mixture, frozen sections
were ﬁxed in 4% paraformaldehyde and incubated with rabbit polyclonal
antibody against human NT3 overnight at 4 °C. After washing with
phosphate-buffered saline (PBS), sections were incubated with Cy3-
tagged secondary antibody against the primary antibody applied (imaged
on the red channel). Nuclei were stained with bis-benzimide (DAPI, im-
aged on the blue channel) and glycoproteins on cell surfaces with Alexa
488-taggedwheat germ agglutinin (WGA, imaged on the green channel).
Microscopywas performedwith a LeicaDMRXAdigitalmicroscope (Leica
Mikroskopie und Systeme GmbH, Wetzlar, Germany) equipped with
Slidebook software (I. I. I., Denver, CO).
2.6. Immunoblotting
Immunoblottingwas applied to analyze Runx2, BMP-2, TGF-β1, phos-
phorylated ERK1/2, total ERK1/2, phosphorylated Akt, total Akt and
GAPDH. Cells were lysed in sample buffer (100 mmol/L Tris–HCl,
pH 6.8, 2% SDS, 0.02% bromophenol blue, and 10% glycerol). Protein sam-
pleswere separated on gradient (4%–20%)mini-gels and transferred onto
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). The
membraneswere blockedwith 5% skimmilk solution for 1 hat roomtem-
perature. The blocked membranes were incubated with a primary anti-
body against a protein of interest. After washing with PBS containing
0.05% Tween20, the membranes were incubated with a peroxidase-
linked secondary antibody speciﬁc to the primary antibody applied.
After further wash, membranes were treated with enhanced chemilumi-
nescence reagents. Themembranes were exposed on x-ray ﬁlms. Image J
(Wayne Rasband, National Institutes of Health, Bethesda, MD) was used
to analyze band density.
2.7. Alizarin red staining
Alizarin red staining for calcium deposits was performed as described
previously [14]. Brieﬂy, cell monolayers were washed twice with PBS
and ﬁxed for 15 min in 4% paraformaldehyde, followed by incubation
with0.2%Alizarin red solution (pH4.2) for 2h. Excessivedyewas removed
by washing with distilled water. Alizarin red staining was examined and
photographed with a Nikon Eclipse TS100 microscope (Tokyo, Japan). To
quantitatively analyze Alizarin red stain, wells were rinsed with distilledwater, and Alizarin red stains were bleached with 10% acetic acid at
85 °C. Supernatant was spectrophotometrically analyzed at 450 nm [22].
2.8. Statistical analysis
Data are presented as mean ± SE. Statistical analysis was performed
using StatView software (Abacus Concepts, Calabasas, CA). ANOVA with
the post-hoc Bonferroni/Dunn test was used to analyze differences be-
tween experimental groups, and a paired t test was applied to analyze
data comparisons between normal and diseased AVICs. Statistical signiﬁ-
cance was deﬁned as P ≤ 0.05. Nonparametric Mann–Whitney U test was
performed to conﬁrm the difference of the 2 group comparison. For mul-
tiple group comparisons, nonparametric Kruskal–Wallis test was per-
formed to conﬁrm the differences.
3. Results
3.1. AVICs of diseased human aortic valves produce higher levels of NT3
We analyzed gene expression proﬁles of AVIC isolates from 5 normal
valves and 5 diseased valves by microarray analysis and compared
expression levels of 377 genes. Twenty-six genes were expressed differ-
ently in AVICs of diseased valves in comparison to AVICs of normal valves.
Eleven out of the 26 geneswere up-regulatedwhile 15 geneswere down-
regulated (Table 1). Among these up-regulated genes, NT3 mRNA levels
are doubled (Fig. 1A). We validated the gene expression data by examin-
ing NT3 protein levels in AVICs isolated from normal and diseased valves.
As shown in Fig. 1B, NT3 protein levels in 7 diseased AVIC isolates were
2.3 folds of those in 7 normal AVIC isolates. We applied immunoﬂuores-
cence staining to examine NT3 in tissue sections of normal and diseased
aortic valves. Much higher levels of NT3 (Fig. 1C, red) were found in dis-
eased aortic valves. NT3 is localized in the cytoplasm of interstitial cells
and in extracellular spaces (Fig. 1C). These results indicate that human
AVICs express NT3, and NT3 levels in diseased aortic valves are up-
regulated. The localization of NT3 in AVICs indicates that NT3 is produced
by AVICs and can be secreted into the extracellular spaces to exert an ef-
fect on neighboring AVICs in a paracrine fashion.
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Fig. 1.AVICs of diseased valves express higher levels of NT3. A. AVICswere isolated fromnormal and diseased human aortic valves. Levels of NT3mRNAwere higher inAVIC isolates from 5
diseased aortic valves compared to AVIC isolates from5 normal aortic valves. *P b 0.05. B. A representative immunoblot and densitometric data showelevated cellular levels of NT3 protein
in AVICs of diseased valves in comparison to AVICs of normal aortic valves. n= 7 isolates from different donors in each group; *P b 0.05. C. Normal and diseased human aortic valveswere
stained for NT3 using a speciﬁc antibody. Representative crosscutting images of areas under endothelial layer show higher NT3 immunoreactivity (red) in diseased aortic valves. Nuclei
were stainedwith bis-benzimide (imaged on the blue channel; N) and glycoproteins on cell surfaces and in the interstitial tissuewith Alexa 488-taggedwheat germagglutinin (imaged on
the green channel). NT3 is localized in AVIC cytoplasm (arrow head) and in the interstitial spaces (arrow). 40× objective.
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AVICs
To determine whether NT3 has an effect on AVIC osteogenic re-
sponses, we stimulated normal human AVICs with recombinant NT3
(expressed in mammalian cells, endotoxin free) and analyzed protein
levels of Runx2, TGF-β1 and BMP-2. As shown in Fig. 2A, stimulation of
human AVICs with recombinant human NT3 for 3 days increased
cellular levels of Runx2, TGF-β1 and BMP-2 in a dose-dependentmanner.
To determine whether NT3 stimulation induces calcium deposition, we
stimulated cells grown in a conditioning medium with NT3 for 14 days.
Fig. 2B shows calcium deposition in AVICs cultured in the conditioning
medium. Interestingly, greater levels of calciumdepositionwere observed
in the presence of NT3 in the conditioning medium (Fig. 2B). Thus, NT3
promotes the pro-osteogenic activity in human AVICs.
3.3. NT3 induces the osteogenic responses in human AVICs through
Trk receptors
We previously found that both PAMPs (such as endotoxin and
pepditalglycan) and DAMPs (such as biglycan and oxLDL) induce
the osteogenic responses in human AVICs through mechanismsdependent of TLR2 and TLR4 [13,23,24]. To understand whether
NT3 functions as a DAMP, we examined the effect of blocking TLR2
and TLR4 with neutralizing antibodies on NT3-induced expression
of TGF-β1 and BMP-2. However, neutralization of either of these
two innate immune receptors failed to affect AVIC production of
TGF-β1 and BMP-2 following an exposure to NT3 (not shown). The
results suggest that NT3 elicits the osteogenic responses in human
AVICs independent of TLR2 or TLR4.
NT3 could bind to all Trk receptor isoforms (types A, B and C)with
high afﬁnity to activate downstream signaling. NT3 can also bind to
p75 NTR with low afﬁnity. We analyzed NT3 receptor expression at
the mRNA level in human AVICs. The real-time PCR results in
Fig. 3A show that mRNAs encoding TrkA, TrkB, TrkC and p75 NTR
were detectable in both normal and diseased human AVICs. Levels
of gene expression of these four receptors were comparable between
normal AVICs and diseased AVICs.
In neuronal cells, NT3 mainly signals through the Trk receptors
[25]. To determine the role of Trk receptors in mediating the pro-
osteogenic effect of NT3, we treated AVICs with a pan Trk inhibitor
K252a (0.20 μmol/L) 60 min before NT3 exposure. As shown in
Fig. 3B, inhibition of Trk receptors with K252a essentially abolished
the effect of NT3 on the production of Runx2, TGF-β1 and BMP-2.
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Fig. 2. NT3 induces the osteogenic responses in human AVICs. A. Human AVICs from normal aortic valves were treated with recombinant human NT3 (0.025, 0.05 and 0.10 μg/mL) for
3 days. Representative immunoblots and densitometric data show dose-dependent induction of Runx2, TGF-β1 and BMP-2 by NT3. n = 5 separate experiments using different AVIC
isolates; *P b 0.05 vs. untreated control. B. Human AVICs from normal aortic valves were treated with NT3 (0.10 μg/mL) for 14 days in the conditioning medium (growth medium
supplemented with 10 mmol/L of β-glycerophosphate, 10 nmol/L of vitamin D3, 10 nmol/L of dexamethasone, and 8 mmol/L of CaCl2). Representative images (10× objective for the
high power image) of Alizarin red staining and spectrophotometric data of 2 separate experiments show that cells exposed to NT3 form a greater amount of calcium deposits. High
power images display bigger clusters of calcium deposits in cells exposed to NT3. Regular = regular growth medium.
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involved, we added Fc chimeras speciﬁc to TrkA, TrkB and TrkC to
AVIC culture medium 60 min before NT3 treatment. The immuno-
blotting results in Fig. 3B show that inhibition of each of the three
Trk isoforms attenuated the effect of NT3 on the production of
Runx2, TGF-β1 and BMP-2. Thus, all of the three Trk isoforms play a
role in mediating NT3-induced osteogenic responses in human
AVICs. To determine whether Trk receptors mediate NT3-induced
calcium deposition, we stimulated normal AVICs with NT3, in the
presence or absence of K252a, in the conditioning medium for
14 days. Fig. 3C shows that NT3-induced calcium deposit formation
was essentially abolished by K252a. Together, these results show
that Trk receptors are expressed by human AVICs and that Trk recep-
tors mediate the pro-osteogenic effects of NT3 in human AVICs.3.4. NT3-induces Akt phosphorylation in human AVICs in a Trk-dependent
fashion
Trk receptors are linked to the ERK1/2 and Akt pathways in neu-
rons and other cell types [25–27]. Both ERK1/2 and Akt pathways
have been found to play critical roles in vascular cell calciﬁcation
[28–30]. To determine the effect of NT3 on ERK1/2 and Akt activation
in human AVICs, we stimulated cells with NT3 (0.10 μg/mL) for 0.5 to
24 h and observed that NT3 induces rapid phosphorylation of both
ERK1/2 and Akt (Fig. 4). Interestingly, inhibition of Trk receptorshad no effect on NT3-induced ERK1/2 phosphorylation while NT3-
induced Akt phosphorylation was abrogated by inhibition of Trk re-
ceptors at all the time points examined.3.5. The Akt pathway plays an important role in mediating NT3-induced
osteogenic responses in human AVICs
To determine the role of Trk-mediated Akt activation in the up-
regulation of Runx2, TGF-β1 and BMP-2, we stimulated AVICs with
NT3 for 3 days with orwithout the presence of a speciﬁc Akt inhibitor
(MK2206, 5.0 μM). The results in Fig. 5A show that inhibition of Akt
markedly reduced the protein levels of Runx2, TGF-β1 and BMP-2
in cells treated with NT3. To determine whether Akt plays a role in
NT3-induced calcium deposit formation, we stimulated cells with
NT3, in the presence or absence of MK2206, in conditioning medium
for 14 days. Fig. 5B shows that NT3-induced calcium deposit forma-
tion was essentially abolished by inhibition of Akt.
To determine whether the Trk–Akt pathway also plays a role in
the pro-osteogenic activity of diseased human AVICs, we treated
AVICs from diseased valves with Trk inhibitor K252a or Akt inhibitor
MK2206 in regular growth medium for 3 days or in the conditioning
medium for 14 days. As shown in Fig. 6A, inhibition of Trk receptors
reduced the levels of TGF-β1 and BMP-2 by 45% and 38% (both P b
0.05), respectively. Similar reductions were observed in cells treated
with the Akt inhibitor. More importantly, inhibition of either Trk
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Fig. 3. NT3 induces the osteogenic responses in human AVICs via Trk receptors. A. Comparable mRNA levels of TrkA, TrkB, TrkC and p75 NTR are detected by real-time PCR in normal and
diseased AVICs. n=3. B.Normal AVICswere treatedwithNT3 in thepresence or absenceof a pan Trk inhibitor K252a (0.20 μmol/L), or isoform-selective inhibitors (Fc chimeras speciﬁc for
TrkA, TrkB and TrkC; 2.0 μg/mL each) for 3 days. Representative immunoblots and densitometric data show that inhibition of Trk receptorswith K252a suppressesNT3-inducedproduction
of Runx2, TGF-β1 and BMP-2while the vehicle dimethyl sulfoxide (DMSO, 0.04%) has no effect. Inhibition of each of the three Trk isoforms attenuates the effect of NT3 on the production of
Runx2, TGF-β1 and BMP-2. n=5 separate experiments using different AVIC isolates; *P b 0.05 vs. untreated control; #P b 0.05 vs. NT3 alone orNT3+DMSO. C. Human AVICs fromnormal
aortic valveswere treatedwith NT3 (0.10 μg/mL), in the presence or absence of Trk inhibitor K252a (0.20 μmol/L), for 14 days in the conditioningmedium (growthmedium supplemented
with 10mmol/L ofβ-glycerophosphate, 10 nmol/L of vitaminD3, 10 nmol/L of dexamethasone, and 8mmol/L of CaCl2). Representative images (10× objective for thehigh power image) of
Alizarin red staining and spectrophotometric data of 2 separate experiments show that cells exposed to NT3 or NT3+DMSO form a greater amount of calcium deposits. Inhibition of Trk
receptors suppresses NT3-induced calcium deposit formation.
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(Fig. 6B). However, inhibition of either Trk receptor or Akt had no ef-
fect on Runx2 protein levels. It appears that the Trk–Akt pathway not
only plays a role in the up-regulation of AVIC pro-osteogenic activi-
ties by NT3, but also contributes to themechanism underlying the el-
evated pro-osteogenic activities in AVICs of diseased aortic valves.Fig. 4.NT3 induces Akt phosphorylation in human AVICs in a Trk-dependent fashion. Normal A
inhibitor K252a (0.20 μmol/L). Representative immunoblots of 3 separate experiments show
suppresses NT3-induced Akt phosphorylation, but has no effect on NT3-induced ERK1/2 phosp4. Discussion
In this study, we obseved that AVICs of diseased human aortic valves
express greater levels of NT3 mRNA and protein than AVICs of normal
aortic valves. NT3 is capable of up-regulating the production of Runx2,
TGF-β1 and BMP-2 in human AVICs. More importantly, NT3 promotesVICs were treated with NT3 (0.10 μg/mL) for 0.5 to 24 h in the presence or absence of Trk
that NT3 induces the phosphorylation of ERK1/2 and Akt. Inhibition of Trk receptors
horylation. p = phospho; t = total.
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Fig. 5. Inhibition of Akt abrogates the effect of NT3 on the osteogenic responses in human AVICs. A. Normal AVICs were treated with NT3 (0.10 μg/mL) in the presence or absence of Akt
inhibitor MK2206 (5.0 μM). Representative immunoblots and densitometric data show that inhibition of Akt reduces Runx2, TGF-β1 and BMP-2 levels in cells exposed to NT3. n = 5
separate experiments using different AVIC isolates; *P b 0.05 vs. untreated control; #P b 0.05 vs. NT3 alone. B. Normal AVICswere treatedwith NT3 (0.10 μg/mL) in the presence or absence
of Akt inhibitor MK2206 (5.0 μM) for 14 days in the conditioningmedium (growthmedium supplementedwith 10mmol/L of β-glycerophosphate, 10 nmol/L of vitamin D3, 10 nmol/L of
dexamethasone, and 8mmol/L of CaCl2). Representative images (10× objective for the high power image) of Alizarin red staining and spectrophotometric data of 2 separate experiments
show that NT3-induced calcium deposit formation is suppressed by Akt inhibitor.
1946 Q. Yao et al. / Biochimica et Biophysica Acta 1852 (2015) 1940–1949calcium deposition in humanAVIC cultures. The pro-osteogenic effect of
NT3 is mediated primarily by the Trk–Akt axis. Thus, NT3 is a novel pro-
osteogenic mediator in human aortic valves. These ﬁndings providenovel insights into the molecular mechanism underlying aortic valve
calciﬁcation associated with CAVD and indicate that elevated expres-
sion of this mediator may play a role in aortic valve calciﬁcation.
1947Q. Yao et al. / Biochimica et Biophysica Acta 1852 (2015) 1940–19494.1. Human AVICs express NT3 and neurotrophin receptors
Neurotrophins are highly conserved proteins best characterized
by their critical role in the differentiation and survival of neuronsA
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l)[31]. Binding of neurotrophins to Trk receptors results in receptor auto-
phosphorylation and activation of downstream signaling cascades [25].
It has become increasingly apparent that neurotrophins and their recep-
tors are also expressed in non-neuronal tissues where their functions
are less well described. In this regard, NT3 mRNA has been detected in
the heart, placenta, skin and skeletal muscle [16]. Moreover, TrkB,
TrkC, and NT3 had been found in human atherosclerotic lesions and in
rat and human aortic smooth muscle cells [32]. In the present study,
we observed that human AVICs express NT3 mRNA and that the levels
of NT3 mRNA are up-regulated in AVICs isolated from valve leaﬂets of
patients with CAVD. In validating these data, we found that NT3 protein
is present in human aortic valves and AVICs. AVICs of diseased valves
produce higher levels of NT3 protein. Thus, our ﬁndings demonstrate
that human aortic valves express this neurotrophin and that the expres-
sion of this neurotrophin is up-regulated in diseased human aortic
valves. In addition, we observed that NT3 is localized in AVICs and in
the extracellular spaces between AVICs in aortic valve tissues. The re-
sults suggest that NT3may exert an effect on AVICs through a paracrine
mechanism.
In neuronal cells and dermal ﬁbroblasts, NT3 activates neurotrophin
receptors including TrkA, TrkB and TrkC to induce cell proliferation and
differentiation [31,33]. In the present study, we found that mRNA
encoding TrkA, TrkB and TrkC receptors as well as p75 NTR mRNA are
detectable in human AVICs although the levels of mRNA for these four
neurotrophin receptors are not affected by CAVD.
4.2. NT3 induces AVIC osteogenic responses through Trk receptors
To test the hypothesis that NT3 has a pro-osteogenic effect on AVICs,
we analyzed protein levels of Runx2, TGF-β1 and BMP-2 in AVICs ex-
posed to NT3. Interestingly, stimulation of human AVICs with recombi-
nant human NT3 for 3 days increased cellular levels of Runx2, TGF-β1
and BMP-2 in a dose-dependent fashion. NT3 has been linked to tooth
growth, and it can up-regulate mRNA levels of pro-osteogenic media-
tors, including BMP-2 and ALP, in oral pulp cells [18]. Our results
show that NT3 at 0.10 μg/mL is capable of increasing protein levels
of Runx2, TGF-β1 and BMP-2 in human AVICs. Thus, NT3 is a pro-
osteogenic factor to human AVICs. Runx2, TGF-β1 and BMP-2 are
present in human aortic valves with calciﬁc disease and play important
roles in aortic valve calciﬁcation [8] and vascular calciﬁcation [34]. As
NT3 levels are elevated in diseased aortic valves, and AVICs of diseased
valves express greater levels of NT3, it is likely that NT3 contributes to
the mechanism underlying the up-regulation of Runx2, TGF-β1 and
BMP-2 expression in diseased aortic valves.
More importantly, our results show that stimulation of humanAVICs
with NT3 in the presence of a conditioning medium induces the forma-
tion of calcium deposits, an in vitro readout of pro-osteogenic activity. It
is noteworthy that the conditioningmedium alone induces low levels of
calcium deposition, and addition of NT3 to the conditioning medium
exaggerates calcium deposition. It seems that NT3 synergizes with the
conditioning medium to induce calcium deposition. In this regard, a
synergistic response in AVICs has been reported in the presence of
sphingosine-1 phosphate and lipopolysaccharide [35], as well as in theFig. 6. Inhibition of Trk or Akt attenuates the pro-osteogenic activity in diseased AVICs. A.
Diseased AVICs were cultured in growth medium and treated with Trk inhibitor K252a
(0.20 μmol/L) or Akt inhibitor MK2206 (5.0 μM) for 3 days. Representative immunoblots
and densitometric data of 3 separate experiments show that inhibition of Trk or Akt re-
duces TGF-β1 and BMP-2 levels, but has no effect on Runx2 levels in AVICs of diseased
valves. *P b 0.05 vs. control. B. Diseased AVICs were cultured for 14 days in the condition-
ing medium (growth medium supplemented with 10 mmol/L of β-glycerophosphate, 10
nmol/L of vitaminD3, 10 nmol/L of dexamethasone, and 8mmol/L of CaCl2). Cellswere un-
treated or treated with Trk inhibitor K252a (0.20 μmol/L) or Akt inhibitor MK2206
(5.0 μM). Representative images (10× objective for the high power image) of Alizarin
red staining and spectrophotometric data of 3 separate experiments show that inhibition
of Trk orAkt suppresses calciumdeposit formation inAVICs of diseased valves. *P b 0.05 vs.
control.
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that stimulation of human AVICs with TGF-β1 or BMP-2 induces the
expression of Runx2 and ALP, as well as the formation of calcium
deposits [36]. In addition, neutralization of both BMP-2 and TGF-β1
abolished the expression of Runx2 and ALP, and calcium deposit forma-
tion inducedbybiglycan in humanAVICs [37]. Runx2has been shown to
up-regulate ALP activity and the expression of multiple pro-osteogenic
factors, including osteocalcin, bone sialoprotein and osteopontin in
osteoblastic cells in vitro [38]. Thus, it is reasonable to postulate that
Runx2, TGF-β1 and BMP-2 are involved in AVIC calcium deposit forma-
tion following stimulation with NT3.
TLR2 and TLR4 are important innate immune receptors that
recognize PAMPs [19] and DAMPs [20]. We questioned whether NT3
functions as a DAMP in human AVICs to up-regulate the production of
pro-osteogenic factors. We observed that neutralizing neither of TLR2
or TLR4 fails to reduce TGF-β1 and BMP-2 production by AVIC exposure
to NT3. In contrast, the effect of NT3 on pro-osteogenic factor produc-
tion is essentially abolished by inhibition of Trk receptors with K252a
(a natural alkaloid that inhibits all Trk isoforms by competitively bind-
ing to the catalytic domains) [39]. Thus, NT3 does not function as a
DAMP to human AVICs. It exerts a pro-osteogenic effect on human
AVICs through Trk receptors. While we did not determine the role of
the p75 NTR, the abolishment of NT3 effect by the pan Trk inhibitor
indicates that NT3 induces the osteogenic responses in human AVICs
primarily through Trk receptors. Inhibition of each of the three Trk iso-
forms attenuates the effect of NT3 on the production of Runx2, TGF-β1
and BMP-2. All of the three Trk isoforms appear to play a role in medi-
ating the pro-osteogenic effect of NT3 inhumanAVICs.More important-
ly, inhibition of Trk receptors also suppresses calciumdeposit formation
in AVICs stimulated by NT3.
4.3. The Trk–Akt pathway plays a critical role in mediating the effect of NT3
Trk receptor signaling in most cell types involves MAPKs and the
serine/threonine kinase Akt [16,31]. We found in the present study
that NT3 induces rapid phosphorylation of ERK1/2 and Akt. However,
inhibition of Trk receptors only abolished Akt phosphorylation. Thus,
Trk receptors in human AVICs are linked to the Akt pathway, but not
the ERK1/2 pathway.
Akt signaling has been implicated in the in vitro differentiation
of skeletal cells, such as chondrocytes and osteoblasts [40]. Mice
lacking of Akt1 and Akt2 exhibit delayed bone development [41].
Further, the Akt pathway has been found to mediate Runx2 expres-
sion induced by reactive oxygen species in human AVICs [42] and
vascular smooth muscle cells [43]. Thus the Akt pathway appears to
have an important role in regulating the pro-osteogenic activities.
Our results indicate that the Akt pathway has a role in mediating
NT3-induced production of Runx2, TGF-β1 and BMP-2 by human
AVICs since Trk inhibition suppresses both Akt activation and the oste-
ogenic responses induced by NT3. Indeed, we observed that inhibition
of Akt markedly reduced the effect of NT3 on the production of
Runx2, TGF-β1 and BMP-2. In addition, inhibition of Akt attenuated
NT3-induced calcium deposit formation. Thus, the Trk–Akt axis plays
an important role in mediating the pro-osteogenic effect of NT3 in
human AVICs.
It is noteworthy that inhibition of the Trk–Akt pathway reduces the
levels of TGF-β1 and BMP-2 and attenuates calcium deposition in
AVICs of diseased valves although it has no effect on Runx2 levels.
Thus, this pathway alsomodulates the pro-osteogenic activities of dis-
eases AVICs in the absence of stimulation. The differential effects of the
Trk–Akt blockades on the levels of Runx2, TGF-β1 and BMP-2 indicate
that these proteins have different turnover rates in diseased AVICs.
Nevertheless, the results suggest that the signaling mechanism medi-
ated by the Trk–Akt pathway may play a role in maintaining a pro-
osteogenic phenotype of AVICs in diseased aortic valves. As NT3 is
over-expressed in human aortic valves affected by CAVD, it is possiblethat NT3-mediated signaling contributes to the mechanism underly-
ing the elevated pro-osteogenic activities in AVICs of diseased aortic
valves.
It remains unclear from the present study what receptor mediates
ERK1/2 phosphorylation in human AVICs exposed to NT3. A possibility
is that NT3 induces ERK1/2 phosphorylation through p75 NTR. As the
Trk–Akt pathwaymediates AVIC osteogenic responses to NT3, it is likely
that the activation of ERK1/2 by a Trk-independent mechanism has
an insigniﬁcant role in the osteogenic responses to NT3 observed in
human AVICs.
5. Conclusion
Human AVICs express NT3 and neurotrophin receptors, and AVICs
of diseased human aortic valves display higher levels of NT3 mRNA
and protein. NT3 is capable of up-regulating the production of Runx2,
TGF-β1 and BMP-2, and promoting calcium deposit formation in
human AVICs via the Trk–Akt pathway. The results of the present
study provide the ﬁrst evidence that NT3 is a pro-osteogenic mediator
in human aortic valves and suggest that NT3 plays a role in the mecha-
nism of aortic valve calciﬁcation through up-regulation of AVIC pro-
osteogenic activities.
5.1. Limitations
NT3mRNA and protein levelswere compared between AVIC isolates
from 7 normal aortic valves and AVIC isolates from 7 diseased aortic
valves. The experiments on normal AVICs to determine the effect of
NT3were repeated using isolates from 5 different donors. The relatively
small sample size is a limitation. In addition, the concentrations of
recombinant human NT3 applied may be different from the concentra-
tions of NT3 in the micro-environments surrounding AVICs in valvular
tissue.
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